Bellicum Inc. (NASDAQ: BLCM) stock gained by 28.38% in the current market trading session. Bellicum is a pharmaceutical business in the early stages of development that aims to cure diseases via controlled cell therapies.
>> 7 Top Picks for the Post-Pandemic Economy <<
BLCM stock’ Current Development
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals declared today a major option and license agreement attempting to cover certain intellectual property and technology rights linked to Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, as well as the use of rimiducid which is an agent used to stimulate the safety switch. MD Anderson will have the possibility to include CaspaCIDe into certain cellular therapy initiatives under the terms of this agreement.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Read More
Bellicum’s CaspaCIDe safety switch could make it easier to use cell therapies in situations where cytokine release syndrome and neurotoxicity have been reported, in the search for new targets with on-target/off-tumor safety concerns, and in combination with next-generation greater potency cell therapy constructs.
Rick Fair, President, and CEO of BLCM stated,
They’re excited to broaden their CaspaCIDe partnership with MD Anderson to provide a larger range of cancer-related programmes. The switch technology, they believe, could improve the benefit/risk balance of cell treatments. They want to keep looking for ways to increase its application through external cooperation with other thought leaders in the sector.
Furthermore,
Each option is normally expected to be exercised upon out-licensing of an MD Anderson programme that includes iC9. Bellicum will be paid upfront and will be allowed to be part of the third-party compensation given to MD Anderson. Bellicum will also get a royalty on global sales of the product in the single digits. The financial dealings are kept under wraps for the time being. Bellicum and MD Anderson have agreed to develop the first two programmes concurrently with the agreement’s execution. This deal builds on a prior one that covered CaspaCIDe’s usage in a specific MD Anderson cell therapy programme.
 stock gained by 28.38% in the current market trading session after announcing a global option and license agreement.){kind=link}